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Abstract
Background: Monitoring antimicrobial use and resistance in hospitals are important tools of antimicrobial
stewardship programs. We aimed to determine the association between the use of frequently prescribed antibiotics
and the corresponding resistance rates in Escherichia coli and Klebsiella pneumoniae among the clinical departments
of a tertiary care hospital.
Methods: We performed a retrospective observational study to analyse the use of nine frequently prescribed
antibiotics and the corresponding antimicrobial resistance rates in hospital acquired E. coli and K. pneumoniae
isolates from 18 departments of our institution over 9 years (2008–2016). The main cross-sectional analysis assessed
the hypothetical influence of antibiotic consumption on resistance by mixed logistic regression models.
Results: We found an association between antibiotic use and resistance rates in E. coli for amoxicillin-clavulanic acid
(OR per each step of 5 defined daily dose/100 bed-days 1.07, 95% CI 1.02–1.12; p = 0.004), piperacillin-tazobactam
(OR 2.11, 95% CI 1.45–3.07; p < 0.001), quinolones (OR 1.52, 95% CI 1.25–1.86; p < 0.001) and trimethoprim-
sulfamethoxazole (OR 1.59, 95% CI 1.19–2.13; p = 0.002). Additionally, we found a significant association when all
nine antibiotics were combined in one analysis. The association between consumption and resistance rates was
stronger for nosocomial than for community strains. In K. pneumoniae, we found an association for amoxicillin-
clavulanic acid (OR 1.07, 95% CI 1.01–1.14; p = 0.025) and for trimethoprim-sulfamethoxazole (OR 2.02, 95% CI 1.44–2.84;
p < 0.001). The combined analysis did not show an association between consumption and resistance (OR 1.06, 95% CI
0.99–1.14; p = 0.07).
Conclusions: We documented an association between antibiotic use and resistance rate for amoxicillin-clavulanic acid,
piperacillin-tazobactam, quinolones and trimethoprim-sulfamethoxazole in E. coli and for amoxicillin-clavulanic acid and
trimethoprim-sulfamethoxazole in K. pneumoniae across different hospital departments. Our data will support
stewardship interventions to optimize antibiotic prescribing at a department level.
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Background
Antibiotic resistance in gram-negative bacteria has increased
worldwide [1]. Infections with resistant gram-negative
bacteria are a particularly serious threat to public health
because they are difficult to treat and are associated with
high morbidity and mortality, and great healthcare costs [2].
Escherichia coli (E. coli) and Klebsiella pneumoniae
(K. pneumoniae) are among the most important
gram-negative pathogens in the hospital setting,
accounting for around one fifth of all pathogens causing
healthcare-associated infections in the USA [3]. These
two pathogens are frequent causes of catheter-associated
urinary tract infections (CAUTI), surgical site infections
(SSI) and ventilator-associated pneumonia (VAP) [3].
Risk factors for the emergence of infections with resist-
ant gram-negative bacteria include existing comorbidi-
ties, presence of medical devices, previous invasive
procedures and admission from a long-term care facility
[4]. Despite the widespread belief that the most import-
ant driver in the selection of bacterial resistance is the
use of antimicrobials, the relationship between antibiotic
use and resistance rates across individual departments
within a single hospital is not well studied. Willemsen et
al. comprehensively investigated this relationship in a
teaching hospital in the Netherlands and showed a cor-
relation between ward-specific use and resistance rates
for ciprofloxacin and amoxicillin-clavulanic acid in E.
coli [5]. Compared to Willemsen et al. we have investi-
gated resistance data for K. pneumoniae in addition to E.
coli, included more antibiotics and used the annual
antibiotic consumption per 100 bed-days per department
over 9 years (2008–2016). Our objective was to identify
antibiotics associated with a higher risk of resistance
development in order to optimise the antibiotic prescrib-
ing practice particularly in those departments in our
hospital with the highest antibiotic consumption.
Methods
Study aim
We aimed to determine the association between the use
of frequently prescribed antibiotics and the correspond-
ing resistance rates in E. coli and K. pneumoniae among
the clinical departments of a tertiary care hospital.
Study design
We performed a retrospective observational study of
antibiotic use and antibiotic resistance rates of E. coli
and K. pneumoniae across 18 departments at the Bern
University Hospital in Bern, Switzerland, between January
1st 2008 and December 31st 2016.
Hospital setting
Bern University Hospital is a 950-bed tertiary care teach-
ing hospital that covers all medical specialties and
includes a 30-bed mixed intensive care unit (ICU). There
are around 40′000 admissions annually, resulting in
290′000 patient-days. The following 18 departments
were included in the study: abdominal surgery and
medicine, cardiology, cardiovascular surgery, critical
care, dermatology, general internal medicine, gynecology
and obstetrics, nephrology, neurology, neurosurgery,
oncology and hematology, ophthalmology, orthopedics,
otorhinolaryngology, plastic and hand surgery, rheuma-
tology and clinical immunology, thoracic surgery and
pulmonology, and urology.
Data collection
Data was extracted from Anresis [6], the national sur-
veillance program that collects data on antibiotic resist-
ance and antibiotic consumption in all Swiss hospitals,
including Bern University Hospital.
Antimicrobial susceptibility testing (AST) for the follow-
ing frequently prescribed antibiotics active against wild type
E. coli and K. pneumoniae were included: amoxicillin (only
active against E. coli), amoxicillin-clavulanic acid, ceftriax-
one, cefepime, piperacillin-tazobactam, meropenem, cipro-
floxacin, norfloxacin, trimethoprim-sulfamethoxazole and
gentamicin. Antibiotics mainly prescribed for perioperative
prophylaxis (e.g. cefuroxime) were not included. All E. coli
and K. pneumoniae isolates originated from routine clinical
diagnostics. AST for isolates from urine was routinely
performed only for amoxicillin, amoxicillin-clavulanic acid,
quinolones and trimethoprim-sulfamethoxazole; all other
isolates were tested for all listed antibiotics. Therefore, the
number of tested samples varies for each of the antibiotics.
AST was performed at the Institute for Infectious Diseases
of the University of Bern and was based on breakpoints for
inhibitory zone diameters (disk diffusion method) accord-
ing to the guidelines of the Clinical and Laboratory
Standards Institute (CLSI). Over the study period the
approved version of the 9th, 10th and 11th CLSI edition
were adopted by the laboratory. Intermediate susceptibility
was recorded as resistance. Quinolone resistance was
defined as resistance to at least one of the substances in
this group (e.g. norfloxacin and/or ciprofloxacin). We
included only the last sample per patient per calendar year.
In the main analysis, we included only hospital-acquired
samples, i.e. samples that had been isolated more than
2 days after hospital admission. In subsequent sensitivity
analyses for community-acquired samples, only samples
isolated during the first two hospitalization days were
analysed. In addition, we repeated the analysis using a
stricter definition of hospital-acquired infection including
only the bacterial isolates that had been detected more than
5 days after hospital admission.
The hospital pharmacy provided data on antibiotic
consumption in numbers of packages delivered to each
department from 2008 to 2016. We assumed that
Cusini et al. Antimicrobial Resistance and Infection Control  (2018) 7:89 Page 2 of 11
deliveries to the departments reflected consumption as
all unused antibiotics were returned to the pharmacy
and subtracted for our analyses. All departments used
the same delivery system without significant storage and
without shifting of antibiotics from one department to
another. In the Anresis database the aggregated data
were converted into defined daily doses (DDD) using the
ATC/DDD system promoted by the World Health
Organization [7]. The DDD is the assumed average
maintenance dose per day for an antimicrobial used for
its main indication in adults.
We obtained annual bed-days per department from
the finance and controlling department of Bern Univer-
sity Hospital. In their calculation, the day of admission
and the day of discharge were counted together as one
bed-day. Annual Antibiotic use in DDD/100 bed-days
was calculated for each of the 18 departments.
Statistical analyses
Antibiotic use across the departments was summarized by
median, interquartile range (IQR, lower quartile-upper
quartile) and total range (minimum-maximum) of the
time-averaged data. The change in antibiotic use over time
within each department was analysed with a linear regres-
sion model with year, department and the interaction of
year and department as covariates. The marginal mean
per department and the change per year and department
are presented as DDD/100 bed-days with 95% confidence
intervals (CI).
We used mixed logistic regression to model antibiotic
resistance in dependence of consumption. The main ana-
lysis was cross-sectional (i.e. consumption and resistance
were assessed at the same time) and was restricted to
nosocomial strains. We fitted antibiotic-specific models
that only considered resistance towards and use of a
specific antibiotic and a combined model that considered
data from all antibiotics and treated the antibiotic as ran-
dom effect. The antibiotic-specific model included a fixed
effect for antibiotic use and random intercepts for depart-
ment and year (nested within department). The combined
model included a fixed effect for antibiotic use and ran-
dom intercepts for antibiotic, department (nested within
antibiotic), and year (nested within antibiotic and depart-
ment). Overall resistance proportions and corresponding
95% CI were obtained by marginal predictions. The asso-
ciation of consumption and resistance is expressed as an
odds ratio (OR) per each step of 5 DDD/100 bed-days (i.e.
referring to the incremental change in the odds for resist-
ance for an increase in consumption by 5 DDD/100
bed-days) with corresponding 95% CI.
We performed four sensitivity analyses. First, resistance
was regressed on the antibiotic use of the preceding year
to investigate a potential temporal relation. Second, we
repeated the analysis for community-acquired bacterial
strains to check for a potential spillover of the (hospital)
consumption effect. The strength of the association was
compared with that found for nosocomial strains by fitting
models using both nosocomial and community data with
an additional random intercept for the mode of acquisi-
tion. We compared models with and without the inter-
action of antibiotic use and the site of acquisition using
likelihood ratio tests; the p-value is reported as p-value for
interaction. Third, we performed the analysis using a stric-
ter definition of hospital-acquired infection including only
the strains that were obtained more than 5 days after
hospital admission in the analysis. Fourth, we performed
separate analyses for isolates from urine, blood and other
sites of origin. We calculated a p-value for interaction
from likelihood ratio tests of models with and without
an interaction for consumption and the origin of the
sample. All analyses were done with Stata version 15
(StataCorp. 2017. Stata Statistical Software: Release
15. College Station, TX.)
Results
Antibiotic consumption in 18 individual hospital
departments
The average use of the antibiotics selected for this study
was 48.5 DDD/100 bed-days, corresponding to 62% of
the total antibiotic use in the study departments between
2008 and 2016.
The annual use of these antibiotics varied widely
between the 18 departments, from a mean of 19.4 (95%
CI: 14.7–24.2) DDD/100 bed-days in neurology to a
mean of 117 (95% CI: 112–122) DDD/100 bed-days in
urology (Fig. 1 and Additional file 1: Table S1). Within
the departments the antibiotic use changed unequally
over the study period. It decreased significantly in crit-
ical care, gynecology and obstetrics, nephrology, thoracic
surgery/pulmonology and urology departments, and in-
creased significantly in the orthopedics, plastic and hand
surgery departments. The trends in antibiotic use within
each department are illustrated by fitted lines in Fig. 1
and summarised in Additional file 1: Table S1.
Overall, amoxicillin-clavulanic acid was by far the most
frequently used antibiotic with a median use of 19.0 DDD/
100 bed-days (IQR: 10.0–26.5), followed by cefepime with
3.9 DDD/100 bed-days (IQR 1.7–5.2) and ceftriaxone with
2.6 DDD/100 bed-days (IQR: 2.0–5.3) (Table 1).
Antibiotic resistances in E. coli isolates
The different origins (urine, blood, respiratory tract,
wound swabs and other) of the E. coli isolates, the num-
ber of AST performed for each antibiotic and the time
point of sampling during the hospital stay are shown
in Table 2. Sixty-five percent of the isolates originated
from urine and 11% from blood. For amoxicillin/
ampicillin, amoxicillin-clavulanic acid, quinolones and
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trimethoprim-sulfamethoxazole, 139 department-years
with 2329 (trimethoprim-sulfamethoxazole) and 2330
(other antibiotics) samples, were analysed. For ceftriaxone,
cefepime, piperacillin-tazobactam and gentamicin we
analyzed 119 department-years with 1083 (cefepime) and
1085 (other antibiotics) samples. The resistance rate was
highest for amoxicillin/ampicillin at 62% (95% CI 55–69%),
followed by amoxicillin-clavulanic acid at 39% (95% CI 35–
44%), and trimethoprim-sulfamethoxazole at 32% (95% CI
27–37%) (Table 3). For all tested antibiotics the resistance
rates for hospital-acquired samples was higher than for
community-acquired samples (Additional file 1: Table S3).
Association of antibiotic consumption and resistance in E.
coli isolates
We found a significant positive association between use
and resistance rates in E. coli for amoxicillin-clavulanic
acid (OR per each step of 5 DDD/100 bed-days 1.07, 95%
CI 1.02–1.12; p = 0.004), piperacillin-tazobactam (OR 2.11,
95% CI 1.45–3.07; p < 0.001), quinolones (OR 1.52, 95% CI
1.25–1.86; p < 0.001) and trimethoprim-sulfamethoxazole
(OR 1.59, 95% CI 1.19–2.13; p = 0.002). An association
between antibiotic use and antimicrobial resistance was also
found in the combined analysis (OR 1.09, 95% CI 1.04–
1.14; p < 0.001). No significant association between use and
resistance rates in E. coli were found for amoxicillin/ampi-
cillin, ceftriaxone, cefepime or gentamicin. (Table 3, Fig. 2).
Due to the absence of meropenem-resistant strains of E.
coli the association between meropenem use and the resist-
ance rate could not be studied.
The association between antimicrobial resistance and
the preceding year’s antibiotic consumption was similar
to the analysis for all study antibiotics (Additional file 1:
Table S2). The association of antibiotic use and
Fig. 1 Annual use of the study antibiotics in DDD/100 bed days in 18 departments for the period between 2008 and 2016. The red lines indicate
fitted values from a linear regression model, the dashed line the overall average
Table 1 Annual antibiotic consumption (DDD/100 bed-days) summarized across 18 departments in the years 2008–2016
Median Interquartile range Total range
Amoxicillin/Ampicillin 2.7 1.2–5.2 0.3–8.4
Amoxicillin-clavulanic acid 19.0 10.0–26.5 6.4–85.3
Ceftriaxone 2.6 2.0–5.3 0.5–8.7
Cefepime 3.9 1.7–5.2 0.1–30.2
Piperacillin-tazobactam 0.9 0.4–1.8 0.0–11.1
Meropenem 1.2 0.3–2.7 0.1–9.8
Quinolones 2.4 1.8–3.5 0.8–15.4
Trimethoprim-sulfamethoxazole 1.7 1.0–3.2 0.2–13.3
Gentamicin 0.2 0.1–0.5 0.0–2.4
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resistance appeared to be stronger in hospital-acquired
than in community-acquired strains for most antibi-
otics and a significant effect of resistance on con-
sumption in community strains was only found for
trimethoprim-sulfamethoxazole However, we could
hardly prove systematic differences and a significant
interaction was only found for piperacillin-tazobactam
(p = 0.034) (Additional file 1: Table S3).
Using a stricter definition for hospital-acquired strains
— by only considering samples obtained more than 5 days
after hospital admission — did not have significant
influence on the results and all main findings were identi-
cal (Additional file 1: Table S4). Analysis of subgroups
according to sample origin confirmed an association of
antibiotic use and resistance for amoxicillin/clavulanic
acid, quinolones, trimethoprim-sulfamethoxazole and for
the combined analysis in urine. An association for
piperacillin-tazobactam was only found in the samples
other than urine and blood (Additional file 1: Table S5).
However, we did not find much evidence for systematic
differences and a significant p-value for interaction was
only observed for gentamicin.
Antibiotic resistance in K. pneumoniae isolates
For amoxicillin-clavulanic acid, quinolones and
trimethoprim-sulfamethoxazole we included 115
department-years with 648 samples; for cefepime,
ceftriaxone, gentamicin and piperacillin-tazobactam 92
department-years with 369 samples. Fifty one percent
of the K. pneumoniae samples were isolated from
urine, 14% from blood and 11% from the respiratory
tract (Table 4). The resistance rate was highest for
piperacillin-tazobactam at 21% (95% CI 17–25%), followed
by amoxicillin-clavulanic acid at 17% (95% CI 14–21%)
Table 2 Number of E. coli samples with antimicrobial susceptibility testing (AST) by origin across 18 departments in the years 2008–
2016
Origin of
the samples
Tested for All nosocomial
samples (N = 2330)
Samples obtained after 2 to 5
hospital days (N = 525)
Samples obtained after 5
hospital days (N = 1805)
Urine AM-CL, Amox/AMP, Quinolones, TMP-SMX 1503 (65%) 377 (72%) 1126 (62%)
CFP 256 (11%) 53 (10%) 203 (11%)
CFT, Gent, MERa, PIP-TZ, 258 (11%) 55 (10%) 203 (11%)
Blood AM-CL, Amox/AMP, CFP, CFT, Gentamicin,
MERa, PIP-TZ, Quinolones, TMP-SMX
264 (11%) 32 (6%) 232 (13%)
Respiratory -tract AM-CL, Amox/AMP, CFP, CFT, Gent, MERa,
PIP-TZ, Quinolones, TMP-SMX
86 (4%) 29 (6%) 57 (3%)
Wound swabs AM-CL, Amox/AMP, CFP, CFT, Gent, MERa,
PIP-TZ, Quinolones
83 (4%) 12 (2%) 71 (4%)
TMP-SMX 82 (4%) 12 (2%) 70 (4%)
Other AM-CL, Amox/AMP, CFP, CFT, Gent, MERa,
PIP-TZ, Quinolones, TMP-SMX
394 (17%) 75 (14%) 319 (18%)
Abbreviations: Amox amoxicillin, AMP ampicillin, AM-CL amoxicillin-clavulanic acid, CFP cefepime, CFT ceftriaxone, Gent gentamicin, MER meropenem, PIP-TZ
piperacillin-tazobactam, TMP-SMX trimethoprim-sulfamethoxazole
aNot included in the models for resistance because all samples were susceptible to Meropenem
Table 3 Antibiotic resistance and association with antibiotic use for E. coli
Resistance Association with antibiotic use
No. of tests/strata Proportion resistant (95% CI) Odds ratio (95% CI) p-value
Amoxicillin/Ampicillin 2330 / 139 62 (55–69) 1.08 (0.84–1.40) 0.53
Amoxicillin-clavulanic acid 2330 / 139 39 (35–44) 1.07 (1.02–1.12) 0.004
Ceftriaxone 1085 / 119 18 (13–24) 1.10 (0.68–1.76) 0.71
Cefepime 1083 / 119 8 (6–12) 1.06 (0.90–1.25) 0.49
Piperacillin-tazobactam 1085 / 119 17 (13–21) 2.11 (1.45–3.07) < 0.001
Quinolones 2330 / 139 20 (17–23) 1.52 (1.25–1.86) < 0.001
Trimethoprim-sulfamethoxazole 2329 / 139 32 (27–37) 1.59 (1.19–2.13) 0.002
Gentamicin 1085 / 119 18 (14–22) 1.30 (0.45–3.71) 0.63
Combined 13,657 / 1032 24 (15–36) 1.09 (1.04–1.14) < 0.001
Results from logistic mixed models for antibiotic resistance in relation to consumption. Odds ratios represent the change in the odds for resistance per increase in
antibiotic use by 5 DDD/100 bed-days. Strata refer to year/department combinations
CI confidence interval
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Fig. 2 Comparison of the proportions of resistant nosocomial E. coli and antibiotic use. Each point indicates the time-averaged values for an
individual department for the period between 2008 and 2016. The size corresponds to the number of bacteria tested for resistance, i.e. reflects
the precision of the resistance estimate. The dashed lines indicate the fitted value from the logistic mixed models
Table 4 Number of K. pneumoniae samples with antimicrobial susceptibility testing (AST) by origin across 18 departments in the
years 2008–2016
Origin of the
samples
Tested for All nosocomial
samples (N = 648)
Samples obtained after 2 to 5
hospital days (N = 124)
Samples obtained after 5
hospital days (N = 524)
Urine AM-CL, Amox/AMPb, Quinolones, TMP-SMX 329 (51%) 72 (58%) 257 (49%)
CFP, CFT, Gent, MERa, PIP-TZ 51 (8%) 12 (10%) 39 (7%)
Blood AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa,
PIP-TZ, Quinolones, TMP-SMX
89 (14%) 9 (7%) 80 (15%)
Respiratory
samples
AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa,
PIP-TZ, Quinolones, TMP-SMX
69 (11%) 16 (13%) 53 (10%)
Wound
swabs
AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa,
PIP-TZ, Quinolones, TMP-SMX
22 (3%) 3 (2%) 19 (4%)
Other AM-CL, Amox/AMPb, CFP, CFT, Gent, MERa,
PIP-TZ, Quinolones, TMP-SMX
139 (21%) 24 (19%) 115 (22%)
PIP-TZ 138 (21%) 24 (19%) 114 (22%)
Abbreviations: Amox amoxicillin, AMP ampicillin, AM-CL amoxicillin-clavulanic acid, CFP cefepime, CFT ceftriaxone, Gent gentamicin, MER meropenem, PIP-TZ
piperacillin-tazobactam, TMP-SMX trimethoprim-sulfamethoxazole
aNot included in the models for resistance because only two samples were resistant to Meropenem
bNot included in the models for resistance because all samples were resistant to Amoxicillin/Ampicillin
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and trimethoprim-sulfamethoxazole at 15% (95% CI 12–
19%) (Table 5).
Association of antibiotic consumption and resistance in K.
pneumoniae isolates
There was a significant association between use and
resistance rates for amoxicillin-clavulanic acid (OR per 5
DDD/100 patient-days 1.07, 95% CI 1.01–1.14; p = 0.025)
and trimethoprim-sulfamethoxazole (OR 2.02, 95% CI
1.44–2.84; p < 0.001) No association between use and
resistance rates were found for ceftriaxone, cefepime,
piperacillin-tazobactam, quinolones or gentamicin. The
combined analysis did not show an overall association
between consumption and resistance (Table 5, Fig. 3).
We did not analyse meropenem and amoxicillin/ampi-
cillin because only two meropenem-resistant strains
were observed and K. pneumoniae has an intrinsic resist-
ance to amoxicillin/ampicillin.
Using last year’s antibiotic use did not show any major
differences to the main analysis (Additional file 1: Table
S6). In community strains, we observed an association
between antibiotic use and resistance for trimethoprim-
sulfamethoxazole (OR 1.62, 95% CI 1.08–2.42; p = 0.021)
and for quinolones (OR 1.42, 95% CI 1.04–1.96; p = 0.029).
Evidence for an interaction was not found (Additional file 1:
Table S7).
Using a stricter definition for hospital-acquired
strains largely confirmed the main analysis but the ORs
tended to be increased and the combined analysis was
now significant (OR 1.09, 95% CI 1.02–1.18; p = 0.012)
(Additional file 1: Table S8). In the sample origin
subgroups, we only found significant associations for
trimethoprim-sulfamethoxazole use and resistance in
urine and blood samples. We did not observe much
evidence for an influence of sample origin on the relation-
ship of use and resistance (Additional file 1: Table S9).
Discussion
Our analysis showed an association between use and resist-
ance for amoxicillin-clavulanic acid, piperacillin-tazobactam,
quinolones and trimethoprim-sulfamethoxazole in E. coli
and for amoxicillin-clavulanic acid and trimethoprim-
sulfamethoxazole in K. pneumoniae across different
hospital departments.
It is intuitive that antibiotic resistance emerges pre-
dominantly in environments with high antibiotic con-
sumption. This has been shown for individual countries
[8] and individual hospitals [9–11]. It is however con-
ceivable that even antibiotic prescription within individ-
ual departments of the same hospital may affect
bacterial resistance in the patients sharing the same en-
vironment, as bacteria can be transmitted from patient
to patient and antibiotic resistance can spread between
bacteria. In this regard, the results of our study con-
firmed the main findings reported by Willemsen et al.
demonstrating that a higher use of amoxicillin-clavulanic
acid and quinolones was associated with higher anti-
microbial resistance in E. coli.
Interestingly, we only found associations between anti-
biotic use and resistance for some antibiotics and differ-
ent associations between E. coli and K. pneumoniae.
A plausible explanation is the considerable difference
in the quantitative use of the antibiotics studied across
our hospital’s departments. Considering the substantial
use of amoxicillin-clavulanic acid at our institution, it is
not surprising that its use was associated with resistance
in both microorganisms analysed. A wide quantitative
range of antibiotic use across different departments may
also facilitate the detection of an association, as observed
for piperacillin/tazobactam, where the median consump-
tion was low, but the range was very wide.
However, the resistance barrier of the individual anti-
biotics may also be relevant for the emergence of resist-
ance. For cefepime, which is recommended in our
Table 5 Antibiotic resistance and association with antibiotic use for K. pneumoniae
Resistance Association with antibiotic use
No. of tests/strata Proportion resistant (95% CI) Odds ratio (95% CI) p-value
Amoxicillin-clavulanic acid 648 / 115 17 (14–21) 1.07 (1.01–1.14) 0.025
Ceftriaxone 369 / 92 10 (5–18) 1.12 (0.52–2.45) 0.77
Cefepime 369 / 92 3 (1–9) 0.86 (0.59–1.25) 0.43
Piperacillin-tazobactam 369 / 92 21 (17–25) 0.84 (0.61–1.18) 0.32
Quinolones 648 / 115 6 (3–9) 1.37 (0.94–2.01) 0.10
Trimethoprim-sulfamethoxazole 648 / 115 15 (12–19) 2.02 (1.44–2.84) < 0.001
Gentamicin 369 / 92 8 (4–16) 1.82 (0.13–25.42) 0.66
Combined 3420 / 713 12 (8–16) 1.06 (0.99–1.14) 0.07
Results from logistic mixed effects models. The odds ratios represent the relative change in the odds for resistance for an increase in antibiotic use by 5 DDD/100
bed-days. Strata refers to year/department combinations
CI confidence interval
Cusini et al. Antimicrobial Resistance and Infection Control  (2018) 7:89 Page 7 of 11
internal antibiotic guidelines [12] as first-line antibiotic
for several nosocomial infections (e.g. pneumonia and
fever in neutropenia), we did not find an association
between use and resistance, even though it was the sec-
ond most frequently used antibiotic overall. Cefepime is
a robust fourth generation cephalosporin, which is rela-
tively stable against β-lactamases and maintains activity
even against difficult organisms. In contrast, Enterobac-
teriaceae may acquire resistance to quinolones and
trimethoprim-sulfamethoxazole more readily and we
indeed observed significant associations between their
use and resistance in E. coli.
Results for K. pneumoniae were less clear than for E.
coli, mainly because the sample size was much smaller.
In particular, for ceftriaxone, cefepime, piperacillin-tazo-
bactam and gentamicin the number of susceptibility
tests performed for K. pneumoniae (n = 369) was
substantially lower than for E. coli (n = 1085).
Our first sensitivity analysis examined the potential
temporal relationship between the consumption of
antibiotics and the development of resistance a year
later. However, the last year’s use did not have a stronger
influence than the current use. Possible explanations are
the relatively stable antibiotic use over time in our set-
ting or a different timing of the emergence of resistance.
Even a reverse causation is possible — the reduction in
use due to the emergence of resistance.
The antibiotic use varied widely between the different
departments and within the individual departments; there
were significant variations in antibiotic use over time.
Notably, the antibiotic use was high in predominantly sur-
gical departments like urology, plastic and hand surgery,
and otorhinolaryngology. Even though cefuroxime, which
is recommended for perioperative prophylaxis, was not
included in the analysis the high antibiotic use of these
departments is probably due to the frequent use of
amoxicillin-clavulanic acid and quinolones (urology) for
perioperative prophylaxis that in some cases is given
longer than suggested by international guidelines. During
the study period, there were no specific antimicrobial
Fig. 3 Comparison of the proportions of resistant nosocomial K. pneumoniae and antibiotic use. Each point indicates the time-averaged values
for an individual department for the period between 2008 and 2016. The size corresponds to the number of bacteria tested for resistance, i.e.
reflects the precision of the resistance estimate. The dashed lines indicate the fitted value from the logistic mixed models
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stewardship interventions in any hospital department.
Improving perioperative prophylaxis in the mentioned
surgical departments will be a priority in the future.
To address the specificity of the association we com-
pared nosocomial and community strains, given that the
latter was not exposed to antibiotic use in the hospital.
As expected, the association between antibiotic con-
sumption and resistance tended to be systematically
stronger for nosocomial strains than for community
strains in E. coli even though we did not always find
significant interactions. This result is consistent with
another Swiss study showing that strains isolated ≥48 h
after admission were less susceptible than those stem-
ming from the community [13]. The same pattern was
not found for K. pneumoniae, mainly because we did not
observe many clear associations in the first place.
Trimethoprim-sulfamethoxazole, for which the associ-
ation persisted in community-acquired K. pneumoniae
strains, is also frequently prescribed in the outpatient
setting [14]. Furthermore, we could not distinguish
patients with previous contacts with the healthcare
system and some community-acquired infections could
actually be healthcare-associated.
The accuracy of distinguishing community- from
hospital-acquired pathogens plays an important role in
our analyses. We chose a 2-day cut-off according to the
Centers for Disease Control and Prevention (CDC)
definition [15]. A stricter definition for hospital-acquired
samples (i.e. a cut-off of five instead of 2 days after
hospital admission) did not change any of the main find-
ings, as the vast majority of samples (79% for E. coli and
81% for K. pneumoniae) was obtained after 5 days of
hospital admission.
In recent years, several studies have analyzed the
relationship between antibiotic use and development of
resistance in Enterobacteriaceae. Consistent with our
findings, several studies have described an association
between in-hospital antibiotic use and resistance to
quinolones in E. coli [16–18]. This association may be
particularly relevant for Switzerland with its compara-
tively higher quinolone consumption than other Euro-
pean countries [19].
Two other studies have reported associations in E. coli
between amoxicillin-clavulanic acid [5, 20] and
piperacillin-tazobactam [21, 22]. The main discrepancy
between our results and those of other studies is the
absence of an association between the use of ceftriaxone
and the emergence of third-generation cephalosporin
resistance in our study [20, 23, 24]. This may be due to a
relatively low median use of ceftriaxone of 2.6 DDD/100
patient days compared to other studies.
Our study has several limitations. First, the number of
AST available differed considerably among the antibiotics
and the sample size was low for some. The majority of
samples (65% of E. coli, and 51% of K. pneumoniae)
originated from urine and a complete AST of these
samples is only performed if routine testing shows several
resistances. Therefore, the resistance data for cefepime,
ceftriaxone, piperacillin-tazobactam and gentamicin was
only available in one sixth of the urine samples. The low
sample size reduces the power of the analysis, which was
particularly problematic for K. pneumoniae where it
severely hampered the conclusions. Moreover testing
some antibiotics only in higher resistant isolates may lead
to an overestimation of resistance in urinary samples
against these antibiotics, due to sampling bias. Second,
this was a single-centre study, therefore our results may
not be generalizable to other contexts with potential
differences in case-mix and epidemiologic characteristics.
Third, we could not take into account individual risk
factors for infections with resistant microorganisms (such
as underlying diseases or previous antimicrobial therapy),
because of the anonymization of the samples. Fourth, we
did not analyse the association between the use of one
particular antibiotic and the resistance to a second anti-
biotic. Fifth, the antibiotic consumption expressed in
DDD per 100 bed-days does not reflect the adequacy of
treatment in terms of proper dosage and duration. Sixth,
we calculated antibiotic use based on deliveries to the
hospital departments rather than administration to the
patients. The departments of our hospital are advised to
order only those antibiotics that are needed for daily use.
Antibiotics that are delivered to the departments but are
for some reason not administrated to the patients must be
returned to the hospital pharmacy. We subtracted the
returned antibiotics from the deliveries and are confident
that our data reflect the real antibiotic administration to
the patients.
However, to the best of our knowledge, our study is the
first comprehensive analysis of the use of the most
important antibiotics for the treatment of gram-negative
bacteria and corresponding antimicrobial resistance across
multiple departments within one institution. We included
all clinical E. coli and K. pneumoniae samples isolated
across 18 departments at our institution over the study
period of 9 years and used the well-established, standard-
ized ATC/DDD system. The study therefore has import-
ant relevance for clinical practice.
Conclusions
We have demonstrated that antibiotic use in different
hospital departments is associated with resistance rates
in E. coli and in K. pneumoniae for some but not all
antibiotics and antibiotics differ in the strength of the
association. Despite a high consumption of cefepime we
could not demonstrate an association between its use and
resistance rates. We will therefore continue to promote
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the use of cefepime over piperacillin/tazobactam as an
empiric broad-spectrum antibiotic in our guidelines.
Keeping resistance in Enterobacteriaceae in check
requires a comprehensive approach including infection
control strategies and an antibiotic stewardship program.
Our data support targeted antibiotic stewardship inter-
ventions, such as department-specific or antimicrobial
agent-specific interventions, to improve antimicrobial
prescribing and reduce the development of antimicrobial
resistance.
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